Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610388 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01610388 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 61 participants.
The verdict
NCT01610388, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This first time in human (FTIH) study will be the first administration of GSK1322322 as an intravenous formulation and will investigate safety, tolerability, and pharmacokinetics in healthy subjects. One cohort of subjects will undergo bronchoalveolar lavage (BAL) for determination of GSK1322322 concentrations in lung with simultaneous comparison to plasma concentrations to evaluate drug penetration in the lung. The study will evaluate the absolute bioavailability of an oral tablet formulation as compared to the IV formulation.In addition, Amendment 01 will enable the investigation of an improved IV formulation (GSK1322322J mesylate salt) in an additional repeat dosing cohort and the supra-therapeutic cohort.
Interventions
- DRUG 500mg IV GSK1322322/placebo
- DRUG 1000mg oral GSK1322322/placebo
- DRUG 1000mg IV GSK1322322/placebo
- DRUG 1500mg oral GSK1322322/placebo dose
- DRUG 1500mg IV GSK1322322/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-09-13 |
| Est. Completion | 2012-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610388
The ClinicalTrials.gov registry entry for NCT01610388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 500mg IV GSK1322322/placebo is the first listed.
NCT01610388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01610388 about?
NCT01610388 is a clinical study titled "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects". This first time in human (FTIH) study will be the first administration of GSK1322322 as an intravenous formulation and will investigate safety, tolerability, and pharmacokinetics in healthy subjects. One cohort of subjects will undergo bronchoalveolar lavage (BAL) for determination of GSK1322322 con...
What is the current status of trial NCT01610388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2011-09-13. Estimated completion is 2012-01-26.
What interventions are being tested in trial NCT01610388?
The interventions under investigation include: 500mg IV GSK1322322/placebo (DRUG), 1000mg oral GSK1322322/placebo (DRUG), 1000mg IV GSK1322322/placebo (DRUG), 1500mg oral GSK1322322/placebo dose (DRUG), 1500mg IV GSK1322322/placebo (DRUG).
Who is sponsoring clinical trial NCT01610388?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.